These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11429028)

  • 21. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.
    Imamura T; Yokosuka O; Chiba T; Kanda T; Kojima H; Fukai K; Imazeki F; Nishimura M; Saito Y; Saisho H
    Leuk Lymphoma; 2005 Jun; 46(6):915-7. PubMed ID: 16019538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient.
    Mutimer D; Pillay D; Shields P; Cane P; Ratcliffe D; Martin B; Buchan S; Boxall L; O'Donnell K; Shaw J; Hübscher S; Elias E
    Gut; 2000 Jan; 46(1):107-13. PubMed ID: 10601065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
    Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.
    Ko WJ; Chou NK; Hsu RB; Chen YS; Wang SS; Chu SH; Lai MY
    J Heart Lung Transplant; 2001 Aug; 20(8):865-75. PubMed ID: 11502409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reactivation of hepatitis B associated with immunosuppression].
    Goossens N; Negro F
    Rev Med Suisse; 2013 Sep; 9(396):1566, 1568-71. PubMed ID: 24066463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B in Solid-Organ Transplant Procedures Other Than Liver.
    Halegoua-De Marzio D; Fenkel JM; Doria C
    Exp Clin Transplant; 2017 Apr; 15(2):130-137. PubMed ID: 28338458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation.
    D'Avola D; Herrero JI
    Rev Esp Enferm Dig; 2011 Mar; 103(3):142-9. PubMed ID: 21434717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir.
    Mertens T; Köck J; Hampl W; Schlicht HJ; Tillmann HL; Oldhafer KJ; Manns MP; Arnold R
    J Hepatol; 1996 Dec; 25(6):968-71. PubMed ID: 9007727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of recurrent hepatitis B post-liver transplantation.
    Lok AS
    Liver Transpl; 2002 Oct; 8(10 Suppl 1):S67-73. PubMed ID: 12362302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation.
    Sousa JM; Pareja F; Serrano J; Gómez MA; García I; Tamayo MJ; Díaz C; Martín C; Pascasio JM; Hinojosa R; Pérez-Bernal JB; Cañas E; Sayago M; Bernardos A
    Transplant Proc; 2003 Mar; 35(2):723-4. PubMed ID: 12644112
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of hepatitis B in liver transplant patients.
    Mohanty SR; Cotler SJ
    J Clin Gastroenterol; 2005 Jan; 39(1):58-63. PubMed ID: 15599213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Status of liver and gastrointestinal transplantation at the University of Miami.
    Weppler D; Khan R; Fragulidis GP; Nery JR; Ricordi C; Tzakis AG
    Clin Transpl; 1996; ():187-201. PubMed ID: 9286568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation.
    Lau GK; Liang R; Wu PC; Lee CK; Lim WL; Au WY
    J Hepatol; 1998 Mar; 28(3):359-68. PubMed ID: 9551671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B immune globulin: the US experience.
    Pruett TL; McGory R
    Clin Transplant; 2000; 14 Suppl 2():7-13. PubMed ID: 10965958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.